In Q1 2025, scPharmaceuticals achieved $11.8 million in FUROSCIX revenue, a 93% increase from the same period last year. The company filled 13,900 doses and added over 4,200 unique prescribers. While operating expenses grew due to R&D and commercialization, the company maintained a cash balance of $57.5 million.
Generated $11.8 million in FUROSCIX revenue, up 93% YoY.
Filled approximately 13,900 doses in Q1 2025, a 73% increase YoY.
Gross-to-net discount was 23%, up from 19% in Q4 2024.
Reported a net loss of $19.7 million with $57.5 million in cash reserves.
scPharmaceuticals expects continued momentum in FUROSCIX growth driven by expanded indication and seasonal patient cost benefits, with additional catalysts like the Autoinjector submission in Q3 2025.
Analyze how earnings announcements historically affect stock price performance